The deal and funding database built for biopharma. Curated deal comps, company profiles, pipelines, dedicated analyst support so you do better research faster
Joined January 2017
- Tweets 426
- Following 251
- Followers 432
- Likes 100
150 Photos and videos
Jun 10
Cancer dealmaking in Q1 2026 points to a healthy, broadening financing environment, with capital concentrating in later-stage, higher-conviction assets.
Read our research
na2.hubs.ly/H063NKt0
1
1
162
Jun 9
DealForma data cited by The New York Times shows China has rapidly become a major source of biopharma dealmaking and oncology innovation, intensifying concerns about U.S. competitiveness in drug development.
Read it here
na2.hubs.ly/H0629lL0
1
105
Jun 4
Biopharma therapeutics and platform financing activity in Q1 2026 reflected a strengthening IPO market alongside more selective follow-on and PIPE funding conditions.
Read our research
na2.hubs.ly/H05YM5X0
1
65
May 28
Biopharma therapeutics and platform financing activity in Q1 2026 reflected a strengthening IPO market alongside more selective follow-on and PIPE funding conditions.
Read our research
na2.hubs.ly/H05P4-20
18
May 20
Q1 2026 biopharma therapeutic and platform M&A shifted toward fewer, larger, and higher-quality acquisitions, with buyers prioritizing late-stage, commercially validated, and strategically differentiated assets.
Read our research
na2.hubs.ly/H05DXnW0
1
21
May 12
We’re excited to share that Chris Dokomajilar, Founder & CEO of DealForma, will be speaking at the CELS Canada in the Valley Showcase 2026 on May 14.
Chris will lead a session titled “Biopharma Venture, Licensing, IPOs, and M&A Trends Through Q1 2026.”
na2.hubs.ly/H05rLK00
36
May 12
WSJ cited DealForma data showing that China and Hong Kong companies accounted for 50% of large pharma in-licensing deals with at least $50 million upfront so far this year, underscoring rising global pharma interest in China-originated assets.
na2.hubs.ly/H05rzNr0
29
May 12
Our Q1 2026 review reflects a shift toward fewer, larger, higher-quality biopharma R&D partnerships, with stronger upfront capital deployment and sustained deal flow, reinforcing disciplined investment.
Read our research
na2.hubs.ly/H05rzJz0
41
Apr 29
Early-stage biopharma funding rebounded in 2025, but Q1 2026 is mixed: softer at platform/preclinical, while Phase II–III remains resilient with dollars and check sizes holding near 2025 levels.
1
45
Apr 28
Biopharma and healthcare VC investment rebounded in 2025 to $55.1B (1,309 rounds), up from $48.4B in 2024, with biopharma specifically increasing to $28.6B. Momentum has carried into Q1 2026 with several large $100M rounds.
87
Apr 28
Big pharma in-licensing remains heavily skewed toward early-stage assets, with platform/discovery deals consistently making up ~60–70% of activity, rising to ~75% in 2026 YTD. Late-stage (Phase II–III) deals continue to represent only a small share.
1
1
93
Apr 27
ADC deal activity remained strong in 2025, with total value reaching ~$25.8B across 36 deals and median upfronts rising to ~$60M, signaling continued demand for high-quality assets. In 2026 YTD, activity is more muted (~$0.6B; 6 deals)
1
88
Apr 24
Big pharma in-licensing spend is heavily concentrated in oncology and biologics, with cancer driving the majority of upfront payments each year and biologics/antibodies/ADCs dominating modality spend (peaking at ~$9.7B in 2025).
33
Apr 24
Biopharma & medtech entered 2026 with selective momentum, with J.P. Morgan’s reports — powered by DealForma — highlighting strong licensing, M&A, and early IPO recovery.
Download the full reports for deeper insights.
na2.hubs.ly/H054J2k0
1
22
Apr 24
Upfront payments remain relatively compressed across stages (~$49M–$215M), but total deal value expands significantly in later stages, driven by milestones—peaking around ~$2.0B in Phase II and ~$1.3B in Phase III.
1
1
33
Apr 23
From 2023–2025, upfronts increased with stage, with later-stage deals commanding the highest premiums. In Q1 2026, this trend accelerated—Phase II median upfront hit ~$650M (single deal) and Phase I ~$180M—showing a shift toward fewer, high-value later-stage deals.
43
Apr 23
Large-cap biopharma dealmaking from 2024–2026 YTD is led by Eli Lilly, Roche, and Novartis in volume, with activity heavily skewed toward R&D partnerships over M&A. In terms of value, Novartis ($47.8B), AstraZeneca ($38.7B), and Eli Lilly ($38.0B) lead in in-licensing spend
1
68
Apr 22
Big pharma significantly increased sourcing from Chinese biopharma through 2025, with deal value rising to $68.7B across 19 large transactions, alongside growing upfront payments. In Q1 2026, China accounted for ~50% of big pharma deals and ~75% of upfront capital.
1
558
Apr 22
Licensing upfronts in 2025 were relatively balanced across regions (~$5.0B U.S., $5.1B EMEA, $7.3B APAC), with APAC leading overall. In Q1 2026, activity shifted sharply toward APAC, which generated $3.4B in upfronts, compared to $1.4B in the U.S. and just $0.4B in EMEA.
1
91
Apr 22
Neurology deal activity in 2025 was mixed, with weaker R&D partnerships offset by strong M&A growth, steady venture funding, and improved IPO activity, signaling confidence in later-stage and clinically validated assets.
Read our research
na2.hubs.ly/H0509x_0
1
100